CAR-T Cell Therapy: Fool’s Gold of Immunotherapy
Progress, limits and risks of CAR-T therapy
CAR-T cell therapy is one of the most groundbreaking developments in cancer immunotherapy. By genetically modifying a patient’s T cells, this treatment targets specific cancer antigens with precision. While successful in certain hematologic malignancies, its high cost, adverse effects, and technical demands restrict access. This article explores the science, history, applications, key risks, and the current landscape in Mexico and Latin America. Far from a universal cure, CAR-T therapy requires careful ethical, clinical, and financial evaluation. At Baja Regenerative, we are committed to responsible education and guidance in advanced regenerative and immunological medicine.
In this issue, we explore one of the most sophisticated and technologically advanced therapies in immunology. We will discuss a particularly interesting and essential immune cell: the T lymphocyte. These cells play a key role in defending the body by identifying and destroying abnormal cells, such as those that are infected or cancerous.
Thanks to genetic engineering, a groundbreaking therapy has been developed using these cells: CAR-T cell therapy.
What are CAR-T Cells?
CAR-T stands for “Chimeric Antigen Receptor T-Cell Therapy.” Essentially, the patient’s own T cells are genetically modified in the lab to express a new type of receptor on their surface—a chimeric receptor.
This receptor is a hybrid structure that combines two functions:
- An external part (similar to an antibody) that specifically recognizes a molecule or antigen present on the tumor cell.
- An internal part that activates the T cell to destroy the target once it is recognized.
In simpler terms, the receptor acts like a specialized lock designed to detect a very specific key on malignant cells. This reprograms the immune system to attack certain types of cancer with great precision.
A Brief History of CAR-T Development
The concept of a chimeric receptor emerged in the 1980s, but it wasn’t until the 2010s that clinical treatments began showing meaningful results. In 2017, the FDA approved the first CAR-T therapy, Kymriah®, for treating acute lymphoblastic leukemia in children and young adults.
Since then, other therapies like Yescarta® and Tecartus® have been approved for lymphomas and multiple myeloma, ushering in a new era of personalized immunotherapy. However, the development has been costly and riddled with technical, clinical, and regulatory challenges.
Current Therapeutic Indications
CAR-T cells are primarily used for hematological malignancies:
- Acute lymphoblastic leukemia (ALL)
- Diffuse large B-cell lymphoma (DLBCL)
- Refractory multiple myeloma
In solid tumors like glioblastoma, breast cancer, or pancreatic cancer, results remain limited due to the lack of specific tumor antigens and the barriers posed by the tumor microenvironment.
The Promise and the Reality
CAR-T therapy offers a powerful promise: to attack cancer using the patient’s own immune system. However, it is not accessible to everyone. Its production is highly specialized, individualized, and expensive—costing more than $400,000 per patient.
Moreover, its effectiveness depends on the cancer type, disease stage, and patient condition. In many cases, benefits are temporary or relapses occur.
Key Disadvantages of CAR-T Therapy
- Cytokine Release Syndrome (CRS): This severe inflammatory response happens when activated CAR-T cells release large amounts of cytokines—molecules that normally coordinate immune responses. Excessive cytokine release can lead to high fever, low blood pressure, breathing difficulties, and in severe cases, multi-organ failure. Specialized medical care is required.
- Neurotoxicity (ICANS): Some patients experience neurological side effects such as headache, confusion, speech loss, tremors, or seizures. Although most cases are reversible, they may require intensive care and close monitoring.
- Manufacturing time: Producing CAR-T cells takes between three and six weeks—a critical period for patients with advanced or fast-progressing disease. The patient must remain stable during this time.
- Autologous therapy: Since the therapy uses the patient’s own T cells, it may not be feasible for individuals with severely weakened immune systems. It also limits availability to those who can undergo cell collection and expansion.
- Specialized infrastructure required: CAR-T therapy must be administered in hospitals equipped with intensive care units and trained personnel to manage potential side effects. Not all healthcare centers are prepared to offer this treatment.
Additionally, it’s important to understand that CAR-T therapy is extremely specific. If a patient receives CAR-T cells that eliminate one type of tumor, those same cells will not be effective if a different type of cancer develops later on. This is because the CAR-T cells are designed to recognize one particular antigen found only on the original tumor.
Think of it like a key made for a specific lock. If a new “lock” (different tumor) appears, the old key (CAR-T cell) won’t work. Even though some tumors may share similar antigens, CAR-T cells are not universal tools—they must be redesigned for each new cancer type.
Are There Alternatives?
Ongoing developments include:
- Allogeneic CAR-T cells: “off-the-shelf” products from healthy donors.
- CAR-NK therapies: using genetically modified Natural Killer cells.
- Bispecific antibodies and TCR-T therapies: for solid tumors.
In addition, activated NK cell immunotherapy and cell-based vaccines are more accessible and faster options in specific clinical scenarios.
The Situation in Mexico and Latin America
In countries like Mexico, CAR-T therapy is not yet widely accessible. Its high cost, lack of specialized hospital infrastructure, and absence of local manufacturing protocols limit its availability. Only a few patients have received CAR-T therapy abroad or through clinical trials.
To date, there is no national public registry documenting how many patients have been treated, but estimates suggest fewer than a hundred. This limited access underscores the urgent need for investment in local cell manufacturing, regulatory frameworks, and clinical training.
Some academic centers like INCan and public universities are exploring CAR-T development, although still in preclinical phases.
Conclusion: Fool’s Gold or Real Gold?
CAR-T cells have transformed treatment options for certain blood cancers, proving that personalized immunotherapy is achievable. However, their cost, complexity, and toxicity require a critical and realistic view. All that glitters is not gold.
At Baja Regenerative, we are committed to providing clear, responsible information on cutting-edge immunotherapies. If you want to learn more about personalized, accessible, and safe treatment options, our team is here to help.
Contact us today for expert guidance and to discover the regenerative and immunological services we offer.
References:
- Moretti A, Buracchi C, Napolitano S, et al. Chimeric antigen receptor therapy for hematological malignancies: a pediatric perspective from leukapheresis to infusion. Blood Transfus. Published online April 16, 2025. doi:10.2450/BloodTransfus.952
- Shao L, Zheng Y, Somerville RP, Stroncek DF, Jin P. New insights on potency assays from recent advances and discoveries in CAR T-cell therapy. Front Immunol. 2025;16:1597888. Published 2025 May 8. doi:10.3389/fimmu.2025.1597888
- Golmohammadi M, Noorbakhsh N, Kavianpour M. CAR-T Cell Therapy: Managing Side Effects and Overcoming Challenges. Adv Biomed Res. 2025;14:38. Published 2025 Apr 30. doi:10.4103/abr.abr_531_23
- Jangavali SS, Hangargekar PB, Gangthade BU, Jadhav SA, Havelikar UA, Joshi AA. From lab to lifesaver: the rise of CAR T-cell therapy in oncology. J Egypt Natl Canc Inst. 2025;37(1):37. Published 2025 May 16. doi:10.1186/s43046-025-00262-6
- Sonar PV, Singh AK, Mandadi S, Sharma NK. Expanding horizons of cancer immunotherapy: hopes and hurdles. Front Oncol. 2025;15:1511560. Published 2025 Apr 25. doi:10.3389/fonc.2025.1511560
- Wang JY, Wang L. CAR-T cell therapy: Where are we now, and where are we heading?. Blood Sci. 2023;5(4):237-248. Published 2023 Nov 2. doi:10.1097/BS9.0000000000000173
